The University of Mississippi
School of Pharmacy Department of Medicinal Chemistry: Prof. Mitch Avery

Research Funding of Professor Mitchell A. Avery


Career Funding from 1985-2010: $47 Million US

 

 

Current Funding As Principal Investigator:

 

University of Mississippi, Personal funds

 

 

Pending Funding as Principal Investigator or Co-PI:

 

R15-NIH, recently MCH-1 proposal not funded.  Under Revision as RO1.

R15-NIH recently Artemisinin proposal not funded.  Under Revision as RO1.

RO1 NIH proposal in preparation for February 5, 2011 deadline.

 

Previous Funding As Principal Investigator:

 

Development and Testing of New Antimalarial Drugs.  Center for Disease Control.  Cooperative Agreement Award No. No.5 U01 CI000211-07.  September 1, 2009 - August 31, 2010.  Extended Funding at $200,000.  15% as PI.

 

Carry-Over Award: Development and Testing of New Antimalarial Drugs.  Center for Disease Control.  Cooperative Agreement Award No.5 U01 CI000211-06.  September 1, 2008 - August 31, 2009.  $57,000.

 

Development and Testing of New Antimalarial Drugs.  Center for Disease Control.  Cooperative Agreement Award No.5 U01 CI000211-01/06.  September 1, 2004 - August 31, 2009.  Total $16,500,000.  25% as PI.

 

Development and Testing of New Antimalarial Drugs.  Center for Disease Control.  Cooperative Agreement Award No. UR3/CCU418652-01/03.  September 1, 2000 - August 31, 2003.  Total, $18,000,000.  15% as PI.

 

Rational Design of Novel Drugs for the Treatment of Emerging Infectious Diseases.  Center for Disease Control.  Cooperative Agreement Grant No. U50/CCU418839-01.  September 1, 2004 - August 31, 2007.  Total, $3,100,000. 15% as PI.

 

Rational Design of Novel Drugs for the Treatment of Emerging Infectious Diseases.  Center for Disease Control.  Cooperative Agreement Grant No. U50/CCU418839-01.   September 1, 2000 - August 31, 2003.  Total, $4,500,000. 15% as PI.

 

Optimization of Total Synthesis and Analog Synthesis of Epothilone B.  License Agreement, NaPro/Tapestry Pharmaceuticals, Inc., September 2001-August 2004.  $450,000.

 

Development of Novel Antifungal, AntiPC Natural Products.  National Institute of Health, 1RO1-AI44623-01A1.  August 1, 1999 - July 31, 2003.  Year Four, $287,239.  15% of PI.

 

Synthesis of Pyrimidine Derivatives, Inhibitors of Leishmanial Dihydrofolate Reductase and Pteridine Reductase 1.  World Health Organization Grant No. M24/181/79 (ID No. A10023).  August 1, 2001-July 31, 2004.  Year Two Pending Funds, $40,000.  10% as PI.

 

Development of Novel Antifungal, AntiPC Natural Products.  National Institute of Health, 1RO1-AI44623-01A1.  August 1, 1999 - July 31, 2003.  Total Direct Costs $850,000.  15% of PI.

 

Design of Novel Anticancer Agents.  Community Medical Education and Research Foundation, Kern Medical Center, Bakersfield, CA.  February 1, 1999 - January 31, 2003.  Year Four, $30,000. 

 

Design, Economic Synthesis and Testing of Analogs of Artemisinin.  World Health Organization Grant No. M20/181/1 (ID No. 970088).  August 1, 1997-July 31, 2001. 

 

Rational Design of Novel, Non-neurotoxic Antimalarials.  National Institute of Health, RO1-AI/GM-40641-O1A1.  August 1, 1997-July 31, 2001. 

 

Structure-Activity Relationship Studies of Eleutherobin, A New Marine Naural Product with             Taxol-like Anticancer Efficacy and Mode of Action.  Elsa U. Pardee Foundation; June 1, 1998 -           May 31, 1999.  $80,918. 

 

Inhibition of Lactate Dehydrogenase-C4 as a New Approach to Male Contraception.  CONRAD       GIG-97-09.  May 15, 1997 - April 1998.  $21,180.

 

            Structure-Activity Relationship Studies of Epothilon B, A Naturally Occuring Macrolactone with      Taxol-like Activity.  Elsa U. Pardee Foundation; June 1, 1996 - May 31, 1998.  $62,342.

 

Graduate Student Training in Organic and Medicinal Chemistry: Application to the Design of           New Antimalarial Drugs.  Department of the Army, Army Research Office (DOD-ARO) Grant     No. DAAL03-92-G-0353, 22 September 1994-21 September 1996, $ 51,319.

 

Directed Synthesis of New Antimalarials using Computer Aided Drug Design.  Department of the Army, Army Research Office (DOD-ARO) Grant No. DAAH04-94-G-0258, 1 August 1994-31 July 1997, $ 97,525.

 

            Synthesis of Analogs of Artemisinin.  World Health Organization Grant No. M20/191/1 (ID No.       930520).  August 1, 1994-July 31, 1995, $49,234.

 

Graduate Student Training in Organic and Medicinal Chemistry: Application to the Design of           New Antimalarial Drugs.  Department of the Army, Army Research Office (DOD-ARO) Grant     No. DAAL03-92-G-0353, 15 August 1992-14 August 1994, $ 20,011.

 

            Chemotherapy of Resistant Malaria: Synthesis of Analogs of Artemisinin and Structure-activity             Relationship Studies.  U.S. Army Medical Research Acquisition Activity (USAMRAA) Contract       No. DAMD17-91-C-1099, 13 June 1991-13 October 1994, $463,741.

 

            Inhibitors of Cholesterol Biosynthesis for the Treatment of Familial Hyper-cholesterolemia.             Mitsubishi Rayon Contract, SRI Project LSC-8938. 1 April 1990-30 March 1993,           $1,300,000.

 

            Synthesis and Testing of Specific LDHC4 Inhibitors as Male Contraceptive Agents. NICHD             Contract No. NIH N01-HD-82901, 1 December 1987 -30 November 1990, $453,582.

 

Drug Development of the Antimalarial Agent Artemisinin: Total Synthesis, Analog Synthesis,           and Structure-Activity Relationship Studies.  U.S. Army Medical Research and Defense Command (USAMRDC) Contract No. DAMD17-88-C-8007, 15 October 1987 - 14 January    1991, $660,924.

 

Synthesis and Testing of Antiprogestational/Postcoital Agents. NICHD Contract No. NIH N01-HD-4-2828.  1 September 1984 - 28 February 1987, $323,221.

 

            Drug Development Against Parasitic Diseases:  Synthesis of the Antimalarial Agent Qinghaosu.        USAMRDC Contract No. DAMD17-85-C-5001, 15 October 1984 - 14 October 1987,

            $465,773.

 

Stereoselective Total Synthesis of Radiolabeled Artemisinin (Qinghaosu).  USAMRDC Contract       No. DAMD 17-88-C-8048, 15 November 1987-14 November 1988, $161,148.

 

            New Topically Active Steroidal Antiinflammatory Agents.  SRI IRD Project No. 870-D32-   PWC.  31 March 1986 - 1 April 1988  $68,000.

 

 

 

As Co-PI:

 

            Synthesis of New Oral Antigonadotropic Androgenic Agents for Male Fertility Control. NICHD       Contract No. NIH N01-HD-4-2826, 1 August 1984 - 31 December 1986, $273,727.  M. Tanabe,        P.I.

 

Synthesis and Testing of Tetrodotoxin and Batrachotoxin Antagonists.USAMRDC Contract No. DAMD 17-86-C-6060, 1 February 1986-31January 1989, $474,509, L. Toll, P.I.

 

Entrepreneurial Training at the Interface between Medicinal Chemistry and Polymer Science, NSF IGERT Training Grant.  June 2004-May 2009.  Total funding ($350K/yr) supports 6 graduate students at UM, 6 at the USM, Hattiesburg.